MariMed Inc. (MRMD) Misses Q2 EPS by 1c ; Provides Outlook

MariMed Inc. (OTC: MRMD) reported Q2 EPS of ($0.02), $0.01 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $40.4 million versus the consensus estimate of $39.6 million.

2024 FINANCIAL GUIDANCE

MariMed's full year 2024 financial targets are based on organic growth of its existing operating assets and do not include new revenue-generating projects requiring regulatory approvals. The Company believes this conservative approach to offering financial targets allows investors and analysts to focus on key operating milestones versus discussions around issues outside the Company's control. As such, the Company's full year 2024 financial targets remain at:

Revenue growth of 5% to 7%;
Non-GAAP Adjusted EBITDA growth of 0% to 2%;
Capital expenditures of $10 million.

For earnings history and earnings-related data on MariMed Inc. (MRMD) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c